
Ivy Zhang
@ivyzhang__
Computational chemist | PhD from @jchodera's group at @MSKCancerCenter @WeillCornell @ivyzhang.bsky.social
ID: 1124148619546910721
03-05-2019 03:08:11
59 Tweet
470 Followers
297 Following

our paper out today in Science Magazine showing how plasticity in early cancer progression influences cells’ ability to communicate w/ their environment! huge thank you & congrats Direna Alonso-Curbelo Lowe Lab dana_peer! science.org/doi/10.1126/sc…


Very excited to share that our work on protein:protein complex free energy calculations has now been published! pubs.acs.org/doi/abs/10.102… Thanks so much to Dominic Rufa, Iván Pulido, Mike Henry 🌈🏳️⚧️, Sukrit Singh from John Chodera (he/him)’s group + Laura Rosen, Kevin Hauser from Vir Biotechnology!

So honored to receive this award! A million thanks and congratulations to my partner in crime Julia Zhao, and to ISCB and ISMB organizers for an all-around amazing conference! One of my favorites to date🎉

So excited to be in Hawaii ICML Conference presenting work w/ Quaid Morris, and to win best poster award!! Thanks for a great workshop ICML-Compbio-Workshop








🚨ANNOUNCEMENT🚨 The COVID Moonshot is now published in Science Magazine! The paper reflects the major contributions of the FAH community and a global network of scientists collaborating to make drug discovery open, globally accessible, and affordable scim.ag/4LB

✨New paper alert Cancer Discovery✨ - GDD-ENS distinguishes 38 cancer types (>96% of patients) w/ high accuracy using routinely collected DNA sequencing data #MSKIMPACT and generalizes well to other gene panels w/o retraining - CNAs (arm/gene level) are key features for classification

Metient reconstructs the migration histories of metastatic cancers by scoring a Pareto front of parsimonious histories. It can be auto-calibrated to different cohorts. Superstar PhD student Divya Koyyalagunta will present at #ISMB2024 in MLCSB Check it out: biorxiv.org/content/10.110…




1/ Thrilled to share an advancement in gene therapy from my PhD in Nature Communications! We've developed a new approach to reduce immune responses while maintaining efficiency—paving the way for safer, more effective therapies. Big thanks to Feng Zhang & Mirco J. Friedrich! bit.ly/redicas9

